Uric acid in CHF: Marker or player in a metabolic disease?

被引：15

作者：

Doehner, Wolfram

von Haehling, Stephan

Anker, Stefan D.

机构：

[1] Humboldt Univ, Div Appl Cachexia Res, Dept Cardiol, Charite,Med Sch, D-13353 Berlin, Germany

[2] Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, Dept Clin Cardiol, London, England

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2007年 / 115卷 / 02期

关键词：

CHRONIC HEART-FAILURE; XANTHINE-OXIDASE INHIBITION; ALLOPURINOL; HYPERURICEMIA; MICE;

D O I：

10.1016/j.ijcard.2006.05.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：156 / 158

页数：3

共 19 条

[1] Inflammatory mediators in chronic heart failure: An overview [J].

Anker, SD ;

von Haehling, S .

HEART, 2004, 90 (04) :464-470

[2] Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].

Anker, SD ;

Doehner, W ;

Rauchhaus, M ;

Sharma, R ;

Francis, D ;

Knosalla, C ;

Davos, CH ;

Cicoira, M ;

Shamim, W ;

Kemp, M ;

Segal, R ;

Osterziel, KJ ;

Leyva, F ;

Hetzer, R ;

Ponikowski, P ;

Coats, AJS .

CIRCULATION, 2003, 107 (15) :1991-1997

[3]

Anker SD, 1997, CIRCULATION, V96, P526

[4] Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].

Becker, MA ;

Schumacher, HR ;

Wortmann, RL ;

MacDonald, PA ;

Eustace, D ;

Palo, WA ;

Streit, J ;

Joseph-Ridge, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461

[5] Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? [J].

Doehner, W ;

Anker, SD .

HEART, 2005, 91 (06) :707-709

[6] Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure - Results from 2 placebo-controlled studies [J].

Doehner, W ;

Schoene, N ;

Rauchhaus, M ;

Leyva-Leon, F ;

Pavitt, DV ;

Reaveley, DA ;

Schuler, G ;

Coats, AJS ;

Anker, SD ;

Hambrecht, R .

CIRCULATION, 2002, 105 (22) :2619-2624

[7] Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance [J].

Doehner, W ;

Rauchhaus, M ;

Florea, VG ;

Sharma, R ;

Bolger, AP ;

Davos, CH ;

Coats, AJS ;

Anker, SD .

AMERICAN HEART JOURNAL, 2001, 141 (05) :792-799

[8]

Doehner W., 2003, J AM COLL CARD S207A, V42

[9] Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure [J].

Freudenberger, RS ;

Schwarz, RP ;

Brown, J ;

Moore, A ;

Mann, D ;

Givertz, MM ;

Colucci, WS ;

Hare, JM .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) :1509-1516

[10]

GALBUSERA C, 2006, BIOCH PHARM

← 1 2 →